Sirolimus

You have access
Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature
KRISTEN D. STARBUCK, RICHARD D. DRAKE, G. THOMAS BUDD and PETER G. ROSE

Anticancer Research November 2016, 36 (11) 6161-6164;
You have access
Early and Severe Radiation Toxicity Associated with Concurrent Sirolimus in an Organ Transplant Recipient with Head and Neck Cutaneous Squamous Cell Carcinoma: A Case Report
BINDU V. MANYAM, TOBENNA I. NWIZU, MELISSA L. RAHE, BRIDGETT A. HARR and SHLOMO A. KOYFMAN

Anticancer Research October 2015, 35 (10) 5511-5514;
You have access
A Retrospective Study of Patients with Malignant PEComa Receiving Treatment with Sirolimus or Temsirolimus: The Royal Marsden Hospital Experience
CHARLOTTE BENSON, JOANNA VITFELL-RASMUSSEN, MARCO MARUZZO, CYRIL FISHER, NINA TUNARIU, SCOTT MITCHELL, OMAR AL-MUDERIS, KHIN THWAY, JAMES LARKIN and IAN JUDSON

Anticancer Research July 2014, 34 (7) 3663-3668;
You have access
Differential Expression of p-mTOR in Cutaneous Basal and Squamous Cell Carcinomas Likely Explains their Different Response to mTOR Inhibitors in Organ-transplant Recipients
GEORGIA KARAYANNOPOULOU, SYLVIE EUVRARD and JEAN KANITAKIS

Anticancer Research September 2013, 33 (9) 3711-3714;
You have access
Levels of Sirolimus in Saliva vs. Blood – the Rationale of Topical Oral Use for Oral Malignancy
ZAKHAR NUDELMAN, NAAMA KESHET, MICHAL DRANITZKI ELHALAL, MICHAEL FRIEDMAN and RAKEFET CZERNINSKI

Anticancer Research February 2013, 33 (2) 661-663;

Main menu

User menu

Search

Sirolimus